Tremelimumab AstraZeneca Evrópusambandið - íslenska - EMA (European Medicines Agency)

tremelimumab astrazeneca

astrazeneca ab - tremelimumab - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Combisyn Stungulyf, dreifa 14,0/3,5 % w/v Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

combisyn stungulyf, dreifa 14,0/3,5 % w/v

norbrook laboratories (ireland) limited - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - stungulyf, dreifa - 14,0/3,5 % w/v

Cloxacillin Vital Pharma Nordic Stungulyfs-/innrennslisstofn, lausn 2 g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cloxacillin vital pharma nordic stungulyfs-/innrennslisstofn, lausn 2 g

vital pharma nordic aps - cloxacillinum natríum - stungulyfs-/innrennslisstofn, lausn - 2 g

Ferinject Stungulyf/innrennslislyf, ördreifa 50 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

ferinject stungulyf/innrennslislyf, ördreifa 50 mg/ml

vifor france - ferricum carboxymaltosum inn - stungulyf/innrennslislyf, ördreifa - 50 mg/ml